Table 2.
Target | CKD relative to healthy | Biological pathways | |
---|---|---|---|
CKD/healthy | p value | ||
PSP | 2.4 | < 0.0001 | Cell proliferation and differentiation |
Desmocollin 2 | 2.3 | < 0.0001 | Cell–cell junctions |
Sclerostin | 2.2 | < 0.0001 | Bone formation |
Cystatin C | 2.2 | < 0.0001 | Protein degradation |
FABPL | 2.1 | < 0.0001 | Fatty acid metabolism |
REG4 | 2.1 | < 0.0001 | Cell proliferation, generation |
tPA | 1.9 | < 0.0001 | Fibrinolysis |
IGFBP-6 | 1.9 | < 0.0001 | Cell proliferation, angiogenesis |
CD59 | 1.9 | < 0.0001 | Complement-induced lysis, T cell activation |
Ephrin-A4 | 1.8 | < 0.0001 | Angiogenesis |
EFNB2 | 1.8 | < 0.0001 | Angiogenesis |
SECTM1 | 1.8 | < 0.0001 | Immune response, inflammation |
Ephrin-A2 | 1.8 | < 0.0001 | Angiogenesis |
SMOC1 | 1.7 | < 0.0001 | Angiogenesis, fibrosis |
Ephrin-A5 | 1.7 | < 0.0001 | Angiogenesis |
VEGF-D | 1.7 | < 0.0001 | Angiogenesis |
PIANP | 1.6 | < 0.0001 | Immune modulation |
Endostatin | 1.6 | < 0.0001 | Angiogenesis |
MIA | 1.6 | < 0.0001 | Cell proliferation, extracellular matrix |
TIMP-1 | 1.5 | < 0.0001 | Extracellular matrix |
VEGF-A | 1.5 | < 0.0001 | Angiogenesis |
NEGR-1 | 1.3 | 0.0001 | Cell adhesion, axon sprouting |
The data are shown ratiometrically for relative fluorescence units (RFU) for CKD/healthy control. CKD: chronic kidney disease, PSP: phosphoserine phosphatase, FABPL: fatty acid-binding protein, liver-type, REG4: regenerating islet-derived protein 4, tPA: tissue plasminogen activator, IGFBP-6: insulin-like growth factor-binding protein, EFN: ephrin, SECTM1: secreted and transmembrane protein 1, Ephrin: Eph family receptor interacting proteins, SMOC1: secreted modular calcium-binding protein 1, VEGF: vascular endothelial growth factor, PIANP: PILR Alpha Associated Neural Protein, MIA: melanoma inhibitory activity, TIMP-1: tissue inhibitor of metalloproteinases, NEGR: neuronal growth regulator.